What is the global market size of Monoclonal Antibody Therapy Market?

Monoclonal Antibody Therapy Market size was valued at USD 133.8 Billion in 2021 and is poised to grow from USD 143.57 Billion in 2022 to USD 252.26 Billion by 2030, at a CAGR of 7.3% during the forecast period (2023-2030).

Global Monoclonal Antibody Therapy Market

Monoclonal Antibody Therapy Market Size, Share, Growth Analysis, By Type(Murine Antibodies, Chimeric Antibodies, Humanised Antibodies and Fully Human Antibodies), By Application(Oncology, Autoimmune Diseases, Infectious Diseases, Inflammatory Conditions and Others.), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35A2527 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 64 | Figures: 75

Monoclonal Antibody Therapy Market Insights

Monoclonal Antibody Therapy Market size was valued at USD 143.56 Billion in 2022 and is poised to grow from USD 154.05 Billion in 2023 to USD 270.68 Billion by 2031, at a CAGR of 7.3% during the forecast period (2023-2030).

One of the primary drivers of the global monoclonal antibody therapy market is the increasing prevalence of chronic diseases, such as cancer, autoimmune disorders, and cardiovascular diseases. Monoclonal antibody therapies have shown promising results in the treatment of these conditions, leading to their growing adoption. Additionally, the aging population and the rise in lifestyle-related diseases have further contributed to the market growth. Technological advancements have enabled the production of highly specific and effective antibodies, increasing their therapeutic efficacy. Additionally, the growing focus on personalised medicine and targeted therapies has further fueled the demand for monoclonal antibody therapies.

US Monoclonal Antibody Therapy Market is poised to grow at a sustainable CAGR for the next forecast year.

Monoclonal Antibody Therapy Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

The global monoclonal antibody therapy market is highly competitive and dynamic, characterised by the presence of numerous pharmaceutical and biotechnology companies. Monoclonal antibody therapy has gained significant traction in the healthcare industry due to its targeted approach and effectiveness in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. The competitive landscape of this market is shaped by factors such as research and development activities, product portfolio, strategic collaborations, and regulatory approvals. 'Roche Holding AG (Switzerland)', 'Johnson & Johnson (US)', 'Novartis International AG (Switzerland)', 'Pfizer Inc. (US)', 'Merck & Co., Inc. (US)', 'Amgen Inc. (US)', 'AstraZeneca PLC (UK)', 'Bristol Myers Squibb Company (US)', 'AbbVie Inc. (US)', 'Eli Lilly and Company (US)', 'Sanofi S.A. (France)', 'GlaxoSmithKline plc (UK)', 'Takeda Pharmaceutical Company Limited (Japan)', 'Biogen Inc. (US)', 'Regeneron Pharmaceuticals, Inc. (US)', 'Moderna, Inc. (US)', 'BioNTech SE (Germany)', 'Alexion Pharmaceuticals, Inc. (US)', 'Gilead Sciences, Inc. (US)', 'CSL Limited (Australia)'

Significant progress in biotechnology and genetic engineering has played a pivotal role in the development of advanced monoclonal antibody therapies. These advancements have facilitated the engineering of antibodies with improved specificity, efficacy, and reduced side effects. Through techniques such as genetic manipulation, researchers can optimise monoclonal antibodies for specific targets, enhancing their therapeutic potential. These breakthroughs have broadened the range of applications for monoclonal antibody therapies and increased their success rates.

Increasing Adoption and Development of Personalised and Targeted Therapies: Monoclonal antibody therapies have gained significant momentum in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. Personalised medicine approaches, such as companion diagnostics, genetic profiling, and biomarker identification, are being integrated into the development and prescription of monoclonal antibody therapies. This trend allows for a more precise and tailored treatment approach, maximising therapeutic efficacy while minimising adverse effects.

In the global monoclonal antibody therapy market, the most dominant region is North America. North America has a strong presence in the market due to factors such as well-established healthcare infrastructure, advanced research and development facilities, and a high adoption rate of monoclonal antibody therapies. The region is home to several prominent pharmaceutical companies and biotechnology firms that are actively involved in the development and commercialization of monoclonal antibody therapies. Additionally, favourable reimbursement policies and government support for innovative therapies contribute to the dominance of North America in the market.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Monoclonal Antibody Therapy Market Insights

Monoclonal Antibody Therapy Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Monoclonal Antibody Therapy Market?

Who are the key vendors in the Monoclonal Antibody Therapy Market?

What is the key driver of Monoclonal Antibody Therapy Market?

What is the key market trend for Monoclonal Antibody Therapy Market?

Which region accounted for the largest share in Monoclonal Antibody Therapy Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300